|Articles|September 17, 2020
Resuming Operations After Fungal Contamination Following COVID-19 Shutdown
Author(s)Bioquell
Despite exhausting all disinfection methods after resuming operations this year, this international biologics provider repeatedly failed Environmental Monitoring test standards, delaying $5M in product release. See how Bioquell’s Rapid Bio Decontamination Service provided a fast, effective solution.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Implementing Automation and Flexible Design for Allogeneic Manufacturing
4
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
5
